Clearmind Medicine Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
I'm PortAI, I can summarize articles.
Clearmind Medicine Inc. announced progress in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, conducted at Yale and Johns Hopkins, completed enrollment and dosing for the first two cohorts with positive safety results and no serious adverse events. The DSMB approved the continuation of the study. Further clinical data will be released as the trial progresses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments